Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study
et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011 (date from earlier preprint)
, Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity Score-matched Cohort Study, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.08.011 (date from earlier preprint)
PSM retrospective with 1,493 patients, showing significantly improved viral clearance with favipiravir. There were no significant differences in clinical improvement or mortality. Mortality was lower (2.1% vs 3.1%), without statistical significance with the small number of events.
|
risk of death, 33.3% lower, RR 0.67, p = 0.50, treatment 8 of 387 (2.1%), control 12 of 387 (3.1%), NNT 97, propensity score matching.
|
|
risk of no clinical improvement, 2.2% higher, RR 1.02, p = 0.73, treatment 26 of 387 (6.7%), control 28 of 387 (7.2%), NNT 194, adjusted per study, inverted to make RR<1 favor treatment, day 28, Cox proportional hazards, propensity score matching, primary outcome.
|
|
days to clinical improvement, 6.2% higher, relative time 1.06, p = 0.07, treatment 387, control 387, propensity score matching.
|
|
risk of no viral clearance, 43.9% lower, RR 0.56, p < 0.001, treatment 78 of 387 (20.2%), control 139 of 387 (35.9%), NNT 6.3, propensity score matching.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Alattar et al., 30 Nov 2021, retrospective, Qatar, peer-reviewed, median age 46.0, 25 authors, study period 23 May, 2020 - 18 July, 2020, average treatment delay 5.0 days.
Contact:
aomrani@hamad.qa.
Abstract: Journal Pre-proof
Favipiravir for the Treatment of Coronavirus
Disease 2019 Pneumonia; a Propensity Scorematched Cohort Study
Rand A. Alattar, Shiema Abdalla, Tasneem
Abdallah, Rashid Kazman, Aseelah Qadmour,
Tawheeda Ibrahim, Bassem Alhariri, Shahd H.
Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi,
Fatma Ben Abid, Joanne Daghfal, Ali Eldeeb,
Kinda Shukri, Ahmed Elsayed, Fatima Rustom,
Musaed Alsamawi, Alaaeldin Abdelmajid, Miguel
A.P. Basulto, Armando A.R. Cobian, Mohamed
Abukhattab, Abdullatif Alkhal, Muna A.
Almaslamani, Ali S. Omrani
PII:
S1876-0341(22)00212-X
DOI:
https://doi.org/10.1016/j.jiph.2022.08.011
Reference:
JIPH1913
To appear in: Journal of Infection and Public Health
Received date: 2 June 2022
Revised date: 21 July 2022
Accepted date: 21 August 2022
Please cite this article as: Rand A. Alattar, Shiema Abdalla, Tasneem Abdallah,
Rashid Kazman, Aseelah Qadmour, Tawheeda Ibrahim, Bassem Alhariri, Shahd
H. Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi, Fatma Ben Abid, Joanne
Daghfal, Ali Eldeeb, Kinda Shukri, Ahmed Elsayed, Fatima Rustom, Musaed
Alsamawi, Alaaeldin Abdelmajid, Miguel A.P. Basulto, Armando A.R. Cobian,
Mohamed Abukhattab, Abdullatif Alkhal, Muna A. Almaslamani and Ali S.
Omrani, Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia;
a Propensity Score-matched Cohort Study, Journal of Infection and Public
Health, (2022) doi:https://doi.org/10.1016/j.jiph.2022.08.011
This is a PDF file of an article that has undergone enhancements after acceptance,
such as the addition of a cover page and metadata, and formatting for readability,
but it is not yet the definitive version of record. This version will undergo
additional copyediting, typesetting and review before it is published in its final
form, but we are providing this version to give early visibility of the article.
Please note that, during the production process, errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier.
Favipiravir for the Treatment of Coronavirus Disease 2019 Pneumonia; a Propensity
Score-matched Cohort Study
Rand A. Alattar,1 Shiema Abdalla,1 Tasneem Abdallah,1 Rashid Kazman,2 Aseelah
Qadmour,2 Tawheeda Ibrahim,1 Bassem Alhariri,2 Shahd H. Shaar,1 Abeer Bajwa,1 Abeir
Alimam,1 Rabia Qazi,1 Fatma Ben Abid,1,3 Joanne Daghfal,1 Ali Eldeeb,3 Kinda Shukri,3
Ahmed Elsayed,1 Fatima Rustom,1 Musaed Alsamawi,1 Alaaeldin Abdelmajid,1 Miguel A. P.
Basulto,4 Armando A. R. Cobian,4 Mohamed Abukhattab,1,3 Abdullatif Alkhal,1,3 Muna A.
oo
1
f
Almaslamani,1,3 Ali S. Omrani,1,3
Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha,
Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation,
e-
2
pr
Qatar
Doha, Qatar
Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar
4
Cuban Hospital, Dukhan, Qatar
Jo
ur
n
Dr Ali S. Omrani
al
Corresponding Author:
Pr
3
PO Box 3050
Communicable Disease Center
Hamad Medical Corporation
Doha, Qatar
Telephone: +974 40254329
E-mail: aomrani@hamad.qa
Abstract
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19
pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥24 hours of
favipiravir were assigned to the favipiravir group, while those who did not formed the nonPage 1 of 14
favipiravir group. The primary outcome was 28-day clinical improvement, defined as..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.